Metabolic profiling of IDH mutation and malignant progression in infiltrating glioma

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Jalbert, Llewellyn E ^a   Elkhaled, Adam ^a,b   Phillips, Joanna J ^a   Neill, Evan ^a   Williams, Aurelia ^a   Crane, Jason C ^a   Olson, Marram P ^a   Molinaro, Annette M ^a   Berger, Mitchel S ^a   Kurhanewicz, John ^a,b   Ronen, Sabrina M ^a   Chang, Susan M ^a   Nelson, Sarah J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE;

BIOPSY; BRAIN TUMOR; CANCER GRADING; CANCER STAGING; DISEASE EXACERBATION; FEMALE; GENETICS; GLIOMA; HUMAN; MALE; METABOLISM; METABOLOME; METABOLOMICS; MUTATION; PROCEDURES;

BIOPSY; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; METABOLOME; METABOLOMICS; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING;

EID: 85016080800     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44792     Document Type: Article

References (45)

1. Riemenschneider, M. J. & Reifenberger, G. Molecular neuropathology of low-grade gliomas and its clinical impact. Adv Tech Stand Neurosurg. 35, 35-64 (2010).
2. Young, R. M., Jamshidi, A., Davis, G. & Sherman, J. H. Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med. 3, 121 (2015).
3. Claus, E. B. et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 38, E6 (2015).
4. Grier, J. T. & Batchelor, T. Low-grade gliomas in adults. Oncologist. 11, 681-693 (2006).
5. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360, 765-73 (2009).
6. Leeper, H. E. et al. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget. 6, 30295-305 (2015).
7. Rohle, D. et al. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science. 340, 626-630 (2013).
8. Turcan, S. et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 4, 1729-36 (2013).
9. Yen, K. E., Bittinger, M. A., Su, S. M. & Fantin, V. R. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 29, 6409-17 (2010).
10. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462, 739-744 (2009).
11. Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483, 479-83 (2012).
12. Andrew, E. R., Bradbury, A. & Eades, R. G. Nuclear magnetic resonance spectra from a crystal rotated at high speed. Nature 182, 1659 (1958).
13. Elkhaled, A. et al. Characterization of metabolites in infiltrating gliomas using ex vivo H high-resolution magic angle spinning spectroscopy. NMR Biomed. 27, 578-93 (2014).
14. Tessem, M. B. et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med. 60, 510-6 (2008).
15. Jalbert, L. E. et al. Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro-Oncology Advanced electronic publication, doi: 10.1093/neuonc/now008 (2016).
16. Basser, P. J. & Pierpaoli, C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson. 111, 209-19 (1996).
17. Hartkens, T., Rueckert, D., Schnabel, J. A., Hawkes, D. J. & Hill, D. L. G. VTK CISG Registration Toolkit: An open source software package for affine and non-rigid registration of single-and multimodal 3D images. BVM Leipzig, Germany, Springer-Verlag 185 (2012).
18. Lee, M. C., Cha, S., Chang, S. M. & Nelson, S. J. Dynamic susceptibility contrast perfusion imaging of radiation effects in normalappearing brain tissue: changes in the first-pass and recirculation phases. J Magn Reson Imaging. 21, 683-93 (2005).
19. Lupo, J. M., Cha, S., Chang, S. M. & Nelson, S. J. Dynamic susceptibility weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. Am J Neuroradiol. 26, 1446-54 (2005).
20. Li, Y. et al. Survival analysis in patients with newly diagnosed glioblastoma using pre-and postradiotherapy MR spectroscopic imaging. J Neurooncol. 15, 607-617 (2013).
21. Crane, J. C., Olson, M. P. & Nelson, S. J. SIVIC: Open-Source, Standards-Based Software for DICOM MR Spectroscopy Workflows. Int J Biomed Imaging 2013, 169526-12 (2013).
22. Meiboom, S. & Gill, D. Modified spin-echo method for measuring nuclear relaxation times. Rev Sci Instrum. 29, 688-691 (1958).
23. Capper, D., Zentgraf, H., Balss, J., Hartmann, C. & Von Deimling, A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 118, 599-601 (2009).
24. Ratiney, H., Albers, M. J., Rabeson, H. & Kurhanewicz, J. Semi-parametric time-domain quantification of HR-MAS data from prostate tissue. NMR Biomed. 23, 1146-1157 (2010).
25. Perez-Llamas, C. & Lopez-Bigas, N. Gitools: Analysis and Visualisation of Genomic Data Using Interactive Heat-Maps. PLoS ONE. 6, e19541 (2011).
26. Marie, S. K. N. & Shinjo, S. M. O. Metabolism and Brain Cancer. Clinics. 66, 33-43 (2011).
27. Chaumeil, M. M. et al. Hyperpolarized 1-13C glutamate: a metabolic imaging biomarker of IDH1-mutation status in glioma. Cancer Res. 74, 4247-57 (2014).
28. Chaumeil, M. M. et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nat Comm. 4, 2429 (2013).
29. Park, I. et al. Changes in Pyruvate Metabolism Detected by Magnetic Resonance Imaging Are Linked to DNA Damage and Serve as a Sensor for Temozolomide Response in Glioblastoma Cells. Cancer Res. 74, 7115-7124 (2014).
30. Backos, D. S., Franklin, C. C. & Reigan, P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol. 83, 1005-12 (2012).
31. Reitman, Z. J. et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 108, 3270-3275 (2011).
32. Shi, J. et al. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation. Tumor Biol. 36, 655 (2015).
33. Chinnaiyan, P. et al. The metabolomics signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 72, 5878-88 (2012).
34. Elkhaled, A., Jalbert, L. E. et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med. 4, 116ra5 (2012).
35. Andronesi, O. C. et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 4, 116ra4 (2012).
36. Choi, C. et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 18, 624-9 (2012).
37. Cooper, A. J. L. & Jeitner, T. M. Central Role of Glutamate Metabolism in the Maintenance of Nitrogen Homeostasis in Normal and Hyperammonemic Brain. Biomolecules. 6, 1-33 (2016).
38. Pope, W. B. et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. Journal of neuro-oncology. 107, 197-205 (2012).
39. De La Fuente, M. I. et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro Oncol. 18, 283-90 (2016).
40. Hartmann, C. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 118, 469-74 (2009).
41. Ward, P. S. et al. The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization. The Journal of Biological Chemistry 288, 3804-3815 (2013).
42. Park, I. et al. Implementation of 3T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients. Ann Biomed Eng. 39, 193-204 (2011).
43. Stefan, D. et al. Quantification of magnetic resonance spectroscopy signals: the jMRUI software package. Meas Sci Technol. 20, 104035 (2009).
44. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. ISBN 3-900051-07-0 (2013).
45. Emir, U. et al. Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 mutations. Cancer Res. 76, 43-9 (2016).